India approves pandemic vaccineThe pharmaceutical company Zydus Cadila announced today it has gained approval from the drug controller general of India to become the first India-based firm to market a pandemic H1N1 vaccine in the country. The vaccine, VaxiFlu-S, will be marketed by Vaxxicare, part of a division of the company that focuses on preventives.
Pandemic vaccine sales totaled $3.4 billion
May 10, 2010
(CIDRAP News) A preliminary study from Germany suggests that an adjuvanted vaccine against the pandemic H1N1 virus was highly effective in adolescents and younger adults and moderately effective in older people, according to a report published yesterday in Eurosurveillance.
May 7, 2010
May 6, 2010
(CIDRAP News) A panel of experts assembled by the World Health Organization (WHO) has published a clinical profile of pandemic H1N1 influenza, using data from scores of studies to fill in details of the broad picture that has emerged over the past year.
(CIDRAP News) Two newly released studies conducted at the University of Utah confirm what many physicians suspected: The news of the start of the H1N1 pandemic in late April 2009 caused panicked parents to bring children to emergency departments in drovesbut what was driving those ER visits was not flu symptoms, but rather the fear of flu.
